Teva Replaces ADSs With an NYSE Direct Listing of Its Shares
Teva will swap its NYSE ADSs one-for-one for ordinary shares that start trading directly on the NYSE on September 14, 2026, with its Tel Aviv listing unchanged.
Tucked into its quarterly earnings release, Teva Pharmaceutical Industries announced a change that matters more to its shareholder register than any single product number: the Israeli drugmaker will retire its American Depositary Share program and list its ordinary shares directly on the New York Stock Exchange. The NYSE direct listing is scheduled to begin trading on Monday, September 14, 2026.
The disclosure came in the company’s July 29 8-K, which attached the second-quarter results as Exhibit 99.1. It is a short paragraph, but it describes a structural change in how US investors hold the stock.
How the switch works
Teva said holders of ADSs will receive ordinary shares on a one-for-one basis. The ADSs will cease trading on the NYSE at the close of trading on Friday, September 11, 2026. The ordinary shares will then commence trading on the NYSE on the next trading day, September 14. Holders keep the same economic position; they simply hold the ordinary shares directly instead of through a depositary receipt.
The company’s ordinary shares that trade on the Tel Aviv Stock Exchange are unaffected, the release said. Teva describes itself as listed on both the NYSE and TASE, and the change keeps that dual presence while removing the depositary layer in New York.
Why Teva says it is doing it
The release gives three goals for the transition: to broaden Teva’s shareholder base, to support potential inclusion in leading indices, and to optimize its cost of capital. It does not elaborate, and it refers readers to its Quarterly Report on Form 10-Q for the second quarter, Part II, Item 5, once available.
The first two goals point at index eligibility and investor access. Some index providers and institutional mandates treat depositary receipts differently from ordinary shares, so a foreign company that lists ordinary shares directly can become eligible for a wider group of buyers. Teva has not said which indices or investors it has in mind, and that reading is an inference from the stated aims rather than a statement in the filing.
A depositary program solves a problem that a direct listing makes unnecessary: giving US investors a security that trades and settles in dollars on a US exchange. Once the ordinary shares themselves are listed there, the extra layer adds cost without adding access.
The quarter behind the announcement
The earnings themselves were mixed. Second-quarter revenue was $4.1 billion, down 1% in US dollars and 3% in local currency, mainly because of lower generics revenue, including a drop in lenalidomide capsules. Teva’s three key innovative brands grew 43% in local currency to more than $1 billion: Austedo reached $696 million, Ajovy $244 million and Uzedy $77 million.
GAAP loss per share was $0.49, including $726 million of expenses tied to the acquisition of Emalex Biosciences for about $700 million in cash. Non-GAAP diluted EPS was $0.02. Teva nudged its 2026 revenue outlook up to $16.5 billion to $16.85 billion, from $16.4 billion to $16.8 billion in April, kept its earnings and cash flow outlook, and raised its expectations for the three brands to about $3.7 billion combined.
What it means for other issuers
For companies that reached US investors through ADS programs, the Teva move shows one alternative: the depositary bank is replaced by direct registration of the ordinary shares. The release gives no figure for savings, so the cost-of-capital argument remains Teva’s own.
The key variables for any similar issuer are home-market listing rules, the mix of US and local holders, and what the exchange requires for ordinary shares. Teva already has an NYSE listing, so the step changes the security that trades there rather than adding a new market.
What to watch
The September 11 and September 14 dates are the two to track, along with the 10-Q disclosure Teva promised. Trading volume and liquidity in the first weeks of ordinary share trading will show whether the move changes who owns the stock.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.


